Company Filing History:
Years Active: 2005
Title: Dalia Cohen: Innovator in Alzheimer's Research
Introduction
Dalia Cohen is a prominent inventor based in Livingston, NJ (US). She has made significant contributions to the field of Alzheimer's research through her innovative work. Her research focuses on the genetic factors associated with Alzheimer's Disease, aiming to identify potential therapeutic targets.
Latest Patents
Dalia Cohen holds a patent for "Transgenic Drosophila melanogaster expressing a β42 in the eye." This patent discloses transgenic flies that exhibit altered phenotypes due to the expression of the Abeta and C99 portions of the human APP gene. The use of these flies is intended to identify genes and their human homologs that may be involved in Alzheimer's Disease. Additionally, the patent discusses the potential of these human homologs as drug targets for developing therapeutics to treat Alzheimer's Disease and other conditions related to defects in the APP pathway. It also includes pharmaceutical compositions comprising substances directed to these genes.
Career Highlights
Dalia Cohen is currently associated with Novartis Corporation, where she continues her research and development efforts. Her work has garnered attention for its potential impact on understanding and treating Alzheimer's Disease.
Collaborations
Dalia collaborates with notable colleagues, including Uwe Jochen Dengler and Alyce Lynn Finelli. These partnerships enhance her research capabilities and contribute to the advancement of knowledge in the field.
Conclusion
Dalia Cohen's innovative work in Alzheimer's research exemplifies the importance of genetic studies in developing effective treatments. Her contributions through her patent and collaborations highlight her commitment to addressing one of the most pressing health challenges of our time.